Basket | Login


Current projects

Our work

All EU-funded or sponsored projects that Alzheimer Europe is currently involved in are listed here. News about these projects, can be found here.

For information about previous projects, please refer to our Annual Reports, which can be found here.

For information on Alzheimer Europe's own projects (e.g. annual publications), please refer to our annual Work Plan here.

AMYPAD (2016-2022)

The "Amyloid imaging to prevent Alzheimer’s disease" project aims to improve the diagnostic workup of patients suspected to have Alzheimer's disease and their management. The partners aim to improve knowledge of the natural history of AD in a pre-symptomatic stage, in order to better select patients for trials. In addition, they will monitor changes in beta amyloid deposition in the brain, in order to quantify the impact of novel therapies.

The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.

PRODEMOS (2018-2023)

The PRODEMOS (Prevention of Dementia using Mobile phone Applications) kicked off in January 2018 and will run for five years. This project aims to make an evidence-based dementia prevention strategy using mobile Health accessible to those at increased risk of dementia who are usually not reached by preventive medicine. From a global perspective, the project will target socio-economically deprived populations in the EU and a population at risk of dementia in China. The final aim is to implement this flexible, fully adaptable mHealth platform in a culturally appropriate form in a range of health care settings across the globe. The PRODEMOS project is led by Eric Moll van Charante and Edo Richard (Academish Medisch Centrum bij de Universiteit van Amsterdam).

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779238.

AD Detect and Prevent (2018-2021)

The Alzheimer’s Disease Detect and Prevent project(ADDP) arrives on the scene at an exciting time for brain health research. In keeping with recent changes in the conceptualisation of and terminology related to Alzheimer’s disease (AD), ADDP is pursuing the ambitious aim of developing a digital tool to improve the detection of AD prior to the possible onset of AD dementia and combining this with programmes for reducing lifestyle risk factors related to developing AD dementia.

The project officially started on 1 November 2018 and is a 2-year project. It has a budget of EUR 3.5 million, distributed across 6 partners, with Danish digital therapeutics company Brain+ leading the consortium. Alzheimer Europe is a partner in this project and is contributing towards the communication and the involvement activities. The latter, is being accomplished by means of a Patient and Public Involvement (PPI) approach.

This project is funded by the European Union’s Horizon 2020 research and innovation programme – Fast Track to Innovation (FTI), grant agreement 820636.

Virtual Brain Cloud (2018-2022)

The VirtualBrainCloud project will develop and validate a decision support system that provides access to high quality multi-disciplinary data for clinical practice. The result will be a cloud-based brain simulation platform to support personalised diagnostics and treatments for neurodegenerative diseases (NDD). The resulting software is tailored to the individual, and bridges multiple scales to identify key mechanisms that predict NDD progression. The interdisciplinary VirtualBrainCloud consortium will also develop robust solutions for legal and ethical matters by interacting with the HumanBrainProject, Alzheimer Europe and ELIXIR, an organization that manages and safeguards EU research data. The project started in December 2018 and will conclude at the end of 2022.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 826421.

SPAN+: Empowering people with dementia (2018-2022)

Empowerment is important for people with dementia in order to remain engaged with significant others, and to remain involved in society and the decision-making process regarding their care and support. Unfortunately, at present, effective empowerment interventions for people with dementia appear to be scarce, both in the Netherlands and internationally. This Dutch project aims to develop an effective empowerment intervention, which is applicable for people with dementia at home as well as in care homes. Together with input of persons with dementia and carers, the project is looking at the effective and useful elements of existing empowerment interventions and to adapt an existing empowerment intervention for people with young-onset dementia ( - only in Dutch), to suit the needs of older people with dementia. They are integrating information from: a European survey, carried out in collaboration with Alzheimer Europe; focus-group meetings with people with dementia, family caregivers and health care professionals; and a literature review on empowerment in people with dementia.  

This study is funded by the programme Memorabel of ZonMw and Deltaplan Dementie of Alzheimer Nederland.

NEURONET (2019-2022)

The NEURONET initiative (Efficiently Networking European Neurodegeneration Research) is a three-year coordination and support action that began in March 2019. Its aim is set up an efficient platform to boost synergy and collaboration across the Innovative Medicines Initiative (IMI) projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

RADAR-AD (2019-2022)

RADAR-AD is a collaborative research initiative that explores the potential of mobile and digital technologies to improve the assessment of Alzheimer’s disease (AD).  The AD terminology in the RADAR-AD project reflects the recent conceptualisation of AD as covering the full spectrum of the disease, including both pre-dementia (preclinical and prodromal AD) and dementia phases (mild to severe AD dementia).

RADAR-AD builds on the knowledge and experience gained in a sister project called RADAR-CNS (Remote Assessment of Disease and Relapse – Central Nervous System), which was launched in 2016 and is exploring remote monitoring in people living with multiple sclerosis, epilepsy and depression.

The RADAR-AD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 806999.

DISTINCT (2019-2023)

DISTINCT stands for “dementia: intersectorial strategy for training and innovation network for current technology”. The main aim of DISTINCT is to develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe. The unique academic and non-academic collaborative partnership of DISTINCT comprises of 13 world leading research organisations across 8 European countries, 9 partners who include Alzheimer Europe, Alzheimer Disease International, the World Federation of Occupational Therapists and 3 small or medium-sized enterprises for technology and dementia care. The University of Nottingham (United Kingdom) manages the DISTINCT programme. DISTINCT is funded by the Marie Skłodowska-Curie Innovative Training Networks (MSC-ITN) under the European Commission's Horizon 2020 programme.

Further information about the project, including details of the students and their projects, can be found at:

MIRIADE (2019 – 2023)

MIRIADE (Multi‐omics Interdisciplinary Research Integration to Address DEmentia diagnosis) is a four years project under the Marie Sklodowska-Curie Actions Programme. The main aim of MIRIADE is to train a new generation of scientists that become experts in effective development of novel biomarkers for dementia. MIRIADE will integrate existing biomarker datasets available within the consortium and form a ‘’dementia disease map’’. The young scientists will develop novel biomarker assays using innovative technologies, and MIRIADE will generate novel innovation insights to generate a blueprint for an efficient biomarker development workflow. MIRIADE thus helps to improve the availability of useful biomarkers in clinical practice. This enables early and specific diagnosis of dementia types. Moreover, these biomarkers will help the development of treatments for dementia.

ADAIR (2020-2022)

A growing body of evidence from epidemiological and animal studies shows that exposure to air pollutants can impair the brain.  The ADAIR project therefore aims to provide crucial mechanistic insight about the effects of air pollutants on the brain in humans and discover biomarkers for air pollution and Alzheimer’s disease (AD) risk prediction. ADAIR addresses a major societal challenge with wide health-related, environmental, economic, scientific, social, and political impact. Lowering the incidence of AD attributable to air pollution and contribution to the mitigation of climate change, are closely linked. The ultimate goal is to develop strategies for early identification of people at risk of AD, and to discover novel targets for preventive strategies in AD.

The ADAIR project is funded by the JPND, for a duration of 36 months. It started in January 2020 and will conclude in December 2022.

RECOGNISED (2020-2023)

In recent years there is mounting evidence that type 2 diabetes (T2D) is associated with cognitive impairment and dementia, which can be considered as a “new” long-term diabetic co-morbid complication with substantial consequences for patients and their families and a significant impact on healthcare systems. RECOGNISED (Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia) will apply innovative approaches to identify the molecular mechanisms involved in the high prevalence of cognitive impairment and dementia in the T2D population. It will use this knowledge to characterise clinical phenotypes based on retinal functional and structural characteristics and serum biomarkers in order to stratify the risk and severity of cognitive decline.

The RECOGNISED project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847749.

The project started in January 2020 and will conclude in December 2023.

PRIME (2020-2024)

Aberrant insulin signalling has a substantial impact on health and socioeconomic factors through its role in diabetes, metabolic syndrome, and obesity. Altered insulin signalling also appears to be implicated in Alzheimer’s disease and – based on our pilot work - in mental illnesses characterised by compulsivity, especially obsessive-compulsive disorder and autism. The PRIME (Prevention and Remediation of Insulin Multimorbidity in Europe) brings together a multidisciplinary team to (1) extend our understanding of insulin multimorbidity across the lifespan, (2) understand the causal mechanisms linking somatic and mental insulin-related illnesses, (3) develop tools for early diagnosis, improved clinical care, and prevention of insulin-related lifespan multimorbidity.  PRIME aims to bring this new knowledge to society, based on e.g. repurposing medication and lifestyle interventions (diet/exercise monitored by mHealth assessment), identifying and validating novel drug targets, developing and testing candidate biomarkers, and by improving existing medical guidelines and policy. Furthermore, educational approaches to inform clinicians, patients, and the general public will be developed.

The PRIME project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847879.

The project started in January 2020, and will conclude in December 2024.

EU-FINGERS (2020-2023)

There is, as yet, no cure available for dementia and Alzheimer disease (AD). With prevention therefore being identified as a global priority, the EU-FINGERS consortium will work towards a novel multimodal precision prevention toolbox, based on an existing successful multimodal lifestyle/vascular prevention model, FINGER (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) and on a precision prevention and early detection (PPED) approach, adapted from cancer research.

The EU-FINGERS Toolbox will include the full range of tools needed to start the next generation of AD dementia prevention trials, within the framework of precision medicine. The aim is to deliver targeted and timely interventions to effectively prevent/delay dementia. The Toolbox will also provide a common framework and align main European cohorts in the AD research field, to deliver results easily implementable in Europe.

The project will align multinational cohorts from observational studies and recent landmark multimodal dementia prevention trials, with new unique long-term trial data. The entire continuum from at-risk and preclinical to prodromal disease stages will be covered, with deep comprehensive clinical, functional and biological assessments.

EU-FINGERS (INTER/JPND/19/BM/14012609) is an EU Joint Programme - Neurodegenerative Disease Research (JPND) project and is supported by the Luxembourg national research fund (FNR).

The project started in January 2020 and will conclude in December 2023.

bPRIDE (2020-2023)

Alzheimer’s dementia, Lewy body dementia, and frontotemporal dementia (FTD) are amongst some of the most common forms of dementia. Each type is caused by different biological factors, and therefore they will  likely require different specific treatments targeting these factors. To be able to develop such effective treatments, it is important to correctly diagnose each dementia type, at the earliest possible stage.

The bPRIDE project (blood PRotein ldentification to Discriminate dEmentias) aims to generate and validate blood tests for early and specific diagnosis of the major dementia types. To successfully achieve these aims, bPRIDE will analyse more than 1,000 blood proteins in over 1,000 patients, who are at different stages of these different dementia types. This will be done using novel and extremely sensitive technologies.

The tools developed within this project could ultimately help to provide specific and early/timely diagnoses, which will empower people with dementia. It will also allow to assign the most suitable novel treatments to the right people, which could strongly facilitate development of successful therapies.

Alzheimer Europe is contributing to this project by supporting its dissemination plan.

You can find out more about the bPRIDE project, here: PROJECT-bPRIDE.pdf (

LETHE (2021-2024)

LETHE (A personalized prediction and intervention model for early detection and reduction of risk factors causing dementia, based on AI and distributed Machine Learning) is a four-year project.

LETHE aims to provide a data-driven risk factor prediction model for older individuals at risk of cognitive decline building upon big data analysis of cross-sectional observational and longitudinal intervention datasets from 4 clinical centres in Europe including the 11- years analysis of the FINGER study. LETHE is set out to establish novel digital biomarkers, for early detection of risk factors, based on unobtrusive ICT-based passive and active monitoring. The aim is to establish a digital-enabled intervention for cognitive decline prevention based on the evolution of a successful protocol (FINGER) evolving into an ICT based preventive lifestyle intervention through individualized profiling, personalized recommendations, feedback and support (FINGER 2.0), well targeted on a population stratified by cost-effective biological biomarkers. The LETHE solution will be tested in a feasibility study validating the achieved improvements.

The LETHE-Project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 101017405.

AI-MIND (2021-2026)

AI-Mind is a 5-year, EU-funded Horizon 2020 project that brings together 15 partners from 8 countries, including academic institutions, medical centers, SMEs and patient associations. Starting in March 2021, AI-Mind will develop an Intelligent Diagnostics toolkit for brain connectivity screening and dementia risk estimation in people with MCI. The aim of AI-Mind is to enable clinicians to perform early population-based screening assessment of dementia risk.

More than 10 million Europeans show signs of mild cognitive impairment (MCI), a condition intermediate between normal brain ageing and dementia. The evolution of MCI differs from person to person, but 50% progress to dementia within five years. Current practice lacks the necessary screening tools to identify those 50% at risk. The patient’s journey typically takes many years of inefficient clinical follow-ups before a conclusive diagnosis is finally reached. AI-Mind will radically shorten this journey to 1 week, through a digital solution that is able to provide a fast and accurate (>95%) prediction for the individual dementia risk.

The AI-Mind platform service, can be easily integrated into existing clinical practices and contains 2 new artificial-intelligence-based tools; The AI-Mind Connector identifies dysfunctional brain networks; The AI-Mind Predictor assesses dementia risk using data from the Connector, advanced cognitive tests, genetic biomarkers and important textual variables.

Tha aim is to set up a European clinical network that will upload patient data to the AI-Mind European cloud platform. The consortium comprises excellent researchers in neuroscience and computer science, from 5 clinical centres, who closely collaborate with 3 SMEs contributing unique technologies, an established data governance body-DNV GL, and Alzheimer Europe.

The project coordinator is Ira Haraldsen of Oslo University Hospital:

ABOARD (2021-2026)

“Stopping Alzheimer’s before it starts” - This is the slogan of a this nationwide, collaborative project in the Netherlands, led by Wiesje van der Flier from Alzheimer Center Amsterdam. ABOARD, short for “A personalized medicine approach for Alzheimer’s disease”, is a public-private project which aims to prepare for a future in which Alzheimer’s disease is stopped before dementia has started. This is realised by: improving timely and accurate diagnosis, developing individualised risk profiles, initiating nationwide data collection, with a focus on patient-reported outcomes, and a focus on prevention strategies by creating awareness around dementia and brainhealth. In addition, the readiness of the Dutch healthcare system for disease-modifying treatment will be evaluated. The ABOARD project has a duration of five years and Jean Georges, Executive Director of Alzheimer Europe is on the Advisory Board. More information about ABOARD, including an animation-video, can be found on the website:



Last Updated: Monday 04 October 2021